An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN.
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Zalutumumab (Primary)
- Indications Head and neck cancer
- Focus Pharmacokinetics
- Sponsors Genmab
- 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
- 20 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.